GR148672X is a specific TGH inhibitor.

Gpr52 antagonist E7 (Scabertopin) is a novel Gpr52-specific small molecule antagonist, reduces mutant HTT levels and rescues Huntington's disease-associated phenotypes in cellular and mouse models..

GPR39 modulator 7 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=20 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.

GPR39 modulator 3 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=5 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.

GPR139 agonist AC4 is a novel small molecule GPR139 receptor agonist with EC50 of 220 nM in calcium mobilization assay in CHO-GPR139 cells. .

GNX-865 is a potent mitochondrial permeability transition pore (mPTP) inhibitor with EC50 of 105 uM (mitochondrial swelling).

GNF-6231 is a potent, orally active and selective Porcupine inhibitor with IC50 of 0.8 nM.

GNE-886 is a potent and selective CECR2 bromodomain inhibitor with IC50 of 16 nM.

GNE-431 is a potent, selective and noncovalent Btk inhibitor with IC50 of 3.2 nM and 2.5 nM for WT Btk and C481S mutant, respectively.

GNE-375 is a potent, selective BRD9 inhibitor with IC50 of 5 nM, displays >480-fold selectivity over BRD4, CECR2, and TAF1.

GNE-293 is a potent and selective PI3Kδ inhibitor with Ki of 0.47 nM, displays 256, 420, 219-fold selectivity over PI3Kα, PI3Kβ, PI3Kγ, respectively.

GNE-2861 is a potent, selective group II PAK (PAK4/5/6) inhibitor with IC50 of 7.5/126/36 nM, respectively, shows selectivity over group I PAKs (IC50=5.42/0.97/>10 uM for PAK1/2/3).

GNE-220 is a potent and selective inhibitor of MAP4K4 with IC50 of 7 nM, also inhibits MINK (MAP4K6), DMPK and KHS1 (MAP4K5) with IC50 of 9 nM, 476 nM and 1,110 nM.

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.

Glycopyrronium bromide (CHF 5259) is a peripherally-acting quaternary ammonium antimuscarinic agent with little or no central nervous system activity.

Glycogen is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria.

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.

Glycodeoxycholate Sodium is a bile salt.

Glucosamine (hydrochloride) is a natural product.

GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM.

GLP-1 receptor agonist-1 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.

Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.

Glimepiride(Amaryl) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

GL-1196 is a PAK4 inhibitor that effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclinD1 pathway and CDK4/6 expression.

GK563 (GK-563) is a potent, selective inhibitor of Ca2+-independent phospholipase A2 (GVIA iPLA2) with IC50 of 1 nM, >20,000-fold selectivity over GIVA cPLA2.

Gimeracil(Gimestat) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination.